In Vitro and In Vivo Toxicometabolomics of the Synthetic Cathinone PCYP Studied by Means of LC-HRMS/MS
Abstract
:1. Introduction
2. Materials and Methods
2.1. Materials and Chemicals
2.2. Sample Preparation and Analysis of pHLM Incubation
2.3. Study Design In Vivo
2.4. Sample Collection In Vivo
2.5. Sample Preparation and Analysis of Rat Blood Plasma and Rat Urine
2.6. LC-HRMS Apparatus
2.7. Data Processing and Statistical Analysis
2.8. Identification of Significant Features
3. Results and Discussion
3.1. Study Design
3.2. Untargeted Data Processing and Statistical Analysis
3.3. Metabolic Pathways of PCYP
3.4. Effect of PCYP on the Rat Metabolome
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Maurer, H.H.; Pfleger, K.; Weber, A.A. Mass Spectral Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites; Wiley-VCH: Weinheim, Germany, 2016. [Google Scholar]
- EMCDDA. European Drug Report 2021; Publications of of the European Union: Lisabon, Portugal, 2021. [Google Scholar] [CrossRef]
- Manier, S.K.; Keller, A.; Schaper, J.; Meyer, M.R. Untargeted metabolomics by high resolution mass spectrometry coupled to normal and reversed phase liquid chromatography as a tool to study the in vitro biotransformation of new psychoactive substances. Sci. Rep. 2019, 9, 2741. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wagmann, L.; Jacobs, C.M.; Meyer, M.R. New Psychoactive Substances: Which Biological Matrix is the Best for Clinical Toxicology Screening? Ther. Drug Monit. 2022, 44, 599–605. [Google Scholar] [CrossRef] [PubMed]
- Kuropka, P.; Zawadzki, M.; Szpot, P. A review of synthetic cathinones emerging in recent years (2019–2022). Forensic Toxicol. 2022, 1–22. [Google Scholar] [CrossRef] [PubMed]
- Simmler, L.D.; Buser, T.A.; Donzelli, M.; Schramm, Y.; Dieu, L.H.; Huwyler, J.; Chaboz, S.; Hoener, M.C.; Liechti, M.E. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 2013, 168, 458–470. [Google Scholar] [CrossRef] [Green Version]
- Simmler, L.D.; Rickli, A.; Hoener, M.C.; Liechti, M.E. Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 2014, 79, 152–160. [Google Scholar] [CrossRef]
- Ellefsen, K.N.; Concheiro, M.; Huestis, M.A. Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. Drug Metab. Rev. 2016, 48, 237–265. [Google Scholar] [CrossRef]
- Soares, J.; Costa, V.M.; Bastos, M.L.; Carvalho, F.; Capela, J.P. An updated review on synthetic cathinones. Arch. Toxicol. 2021, 95, 2895–2940. [Google Scholar] [CrossRef]
- Kolanos, R.; Sakloth, F.; Jain, A.D.; Partilla, J.S.; Baumann, M.H.; Glennon, R.A. Structural Modification of the Designer Stimulant alpha-Pyrrolidinovalerophenone (alpha-PVP) Influences Potency at Dopamine Transporters. ACS Chem. Neurosci. 2015, 6, 1726–1731. [Google Scholar] [CrossRef] [Green Version]
- Araujo, A.M.; Carvalho, M.; Costa, V.M.; Duarte, J.A.; Dinis-Oliveira, R.J.; Bastos, M.L.; Guedes de Pinho, P.; Carvalho, F. In vivo toxicometabolomics reveals multi-organ and urine metabolic changes in mice upon acute exposure to human-relevant doses of 3,4-methylenedioxypyrovalerone (MDPV). Arch. Toxicol. 2021, 95, 509–527. [Google Scholar] [CrossRef]
- Steuer, A.E.; Kaelin, D.; Boxler, M.I.; Eisenbeiss, L.; Holze, F.; Vizeli, P.; Czerwinska, J.; Dargan, P.I.; Abbate, V.; Liechti, M.E.; et al. Comparative Untargeted Metabolomics Analysis of the Psychostimulants 3,4-Methylenedioxy-Methamphetamine (MDMA), Amphetamine, and the Novel Psychoactive Substance Mephedrone after Controlled Drug Administration to Humans. Metabolites 2020, 10, 306. [Google Scholar] [CrossRef]
- Manier, S.K.; Schwermer, F.; Wagmann, L.; Eckstein, N.; Meyer, M.R. Liquid Chromatography-High-Resolution Mass Spectrometry-Based In Vitro Toxicometabolomics of the Synthetic Cathinones 4-MPD and 4-MEAP in Pooled Human Liver Microsomes. Metabolites 2020, 11, 3. [Google Scholar] [CrossRef] [PubMed]
- Manier, S.K.; Wagmann, L.; Flockerzi, V.; Meyer, M.R. Toxicometabolomics of the new psychoactive substances alpha-PBP and alpha-PEP studied in HepaRG cell incubates by means of untargeted metabolomics revealed unexpected amino acid adducts. Arch. Toxicol. 2020, 94, 2047–2059. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hemmer, S.; Wagmann, L.; Meyer, M.R. Altered metabolic pathways elucidated via untargeted in vivo toxicometabolomics in rat urine and plasma samples collected after controlled application of a human equivalent amphetamine dose. Arch. Toxicol. 2021, 95, 3223–3234. [Google Scholar] [CrossRef] [PubMed]
- Zaitsu, K.; Hayashi, Y.; Kusano, M.; Tsuchihashi, H.; Ishii, A. Application of metabolomics to toxicology of drugs of abuse: A mini review of metabolomics approach to acute and chronic toxicity studies. Drug Metab. Pharmacokinet. 2016, 31, 21–26. [Google Scholar] [CrossRef] [PubMed]
- Abraham, A.; Wang, Y.; El Said, K.R.; Plakas, S.M. Characterization of brevetoxin metabolism in Karenia brevis bloom-exposed clams (Mercenaria sp.) by LC-MS/MS. Toxicon 2012, 60, 1030–1040. [Google Scholar] [CrossRef]
- Wang, L.; Wu, N.; Zhao, T.Y.; Li, J. The potential biomarkers of drug addiction: Proteomic and metabolomics challenges. Biomarkers 2016, 21, 678–685. [Google Scholar] [CrossRef]
- Steuer, A.E.; Brockbals, L.; Kraemer, T. Metabolomic Strategies in Biomarker Research-New Approach for Indirect Identification of Drug Consumption and Sample Manipulation in Clinical and Forensic Toxicology? Front. Chem. 2019, 7, 319. [Google Scholar] [CrossRef]
- Hemmer, S.; Manier, S.K.; Fischmann, S.; Westphal, F.; Wagmann, L.; Meyer, M.R. Comparison of Three Untargeted Data Processing Workflows for Evaluating LC-HRMS Metabolomics Data. Metabolites 2020, 10, 378. [Google Scholar] [CrossRef]
- Manier, S.K.; Meyer, M.R. Impact of the used solvent on the reconstitution efficiency of evaporated biosamples for untargeted metabolomics studies. Metabolomics 2020, 16, 34. [Google Scholar] [CrossRef]
- Maurer, H.H.; Meyer, M.R.; Helfer, A.G.; Weber, A.A. Maurer/Meyer/Helfer/Weber MMHW LC-HR-MS/MS Library of Drugs, Poisons, and Their Metabolites; Wiley-VCH: Weinheim, Germany, 2018. [Google Scholar]
- Manier, S.K.; Keller, A.; Meyer, M.R. Automated optimization of XCMS parameters for improved peak picking of liquid chromatography-mass spectrometry data using the coefficient of variation and parameter sweeping for untargeted metabolomics. Drug Test. Anal. 2019, 11, 752–761. [Google Scholar] [CrossRef]
- Wehrens, R.; Hageman, J.A.; van Eeuwijk, F.; Kooke, R.; Flood, P.J.; Wijnker, E.; Keurentjes, J.J.; Lommen, A.; van Eekelen, H.D.; Hall, R.D.; et al. Improved batch correction in untargeted MS-based metabolomics. Metabolomics 2016, 12, 88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adusumilli, R.; Mallick, P. Data Conversion with ProteoWizard msConvert. Methods Mol. Biol. 2017, 1550, 339–368. [Google Scholar] [CrossRef] [PubMed]
- Smith, C.A.; Want, E.J.; O’Maille, G.; Abagyan, R.; Siuzdak, G. XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 2006, 78, 779–787. [Google Scholar] [CrossRef] [PubMed]
- Team, R.C. R: A Language and Environment for Statistical Computing, 3.4.1; R Foundation for Statistical Computing: Vienna, Austria, 2013. [Google Scholar]
- Kuhl, C.; Tautenhahn, R.; Bottcher, C.; Larson, T.R.; Neumann, S. CAMERA: An integrated strategy for compound spectra extraction and annotation of liquid chromatography/mass spectrometry data sets. Anal. Chem. 2012, 84, 283–289. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Broadhurst, D.I.; Kell, D.B. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2006, 2, 171–196. [Google Scholar] [CrossRef] [Green Version]
- van der Maaten, L. Accelerating t-SNE using Tree-Based Algorithms. J. Mach. Learn. Res. 2014, 15, 3221–3245. [Google Scholar]
- van der Maaten, L.; Hinton, G. Visualizing Data using t-SNE. J. Mach. Learn. Res. 2008, 9, 2579–2605. [Google Scholar]
- Sumner, L.W.; Amberg, A.; Barrett, D.; Beale, M.H.; Beger, R.; Daykin, C.A.; Fan, T.W.; Fiehn, O.; Goodacre, R.; Griffin, J.L.; et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 2007, 3, 211–221. [Google Scholar] [CrossRef] [Green Version]
- Asha, S.; Vidyavathi, M. Role of human liver microsomes in in vitro metabolism of drugs-a review. Appl. Biochem. Biotechnol. 2010, 160, 1699–1722. [Google Scholar] [CrossRef]
- Barnes, S.; Benton, H.P.; Casazza, K.; Cooper, S.J.; Cui, X.; Du, X.; Engler, J.; Kabarowski, J.H.; Li, S.; Pathmasiri, W.; et al. Training in metabolomics research. I. Designing the experiment, collecting and extracting samples and generating metabolomics data. J. Mass Spectrom. 2016, 51, 461–475. [Google Scholar] [CrossRef] [Green Version]
- Vervliet, P.; Mortele, O.; Gys, C.; Degreef, M.; Lanckmans, K.; Maudens, K.; Covaci, A.; van Nuijs, A.L.N.; Lai, F.Y. Suspect and non-target screening workflows to investigate the in vitro and in vivo metabolism of the synthetic cannabinoid 5Cl-THJ-018. Drug Test. Anal. 2019, 11, 479–491. [Google Scholar] [CrossRef] [PubMed]
- Barnes, S.; Benton, H.P.; Casazza, K.; Cooper, S.J.; Cui, X.; Du, X.; Engler, J.; Kabarowski, J.H.; Li, S.; Pathmasiri, W.; et al. Training in metabolomics research. II. Processing and statistical analysis of metabolomics data, metabolite identification, pathway analysis, applications of metabolomics and its future. J. Mass Spectrom. 2016, 51, 535–548. [Google Scholar] [CrossRef] [Green Version]
- McClenahan, S.; Gunnell, M.; Owens, M. Pharmacokinetics of alpha-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an alpha-Pyrrolidinovalerophenone Vaccine. J. Pharm. Pharm. Sci. 2021, 24, 267–276. [Google Scholar] [CrossRef] [PubMed]
- Negreira, N.; Erratico, C.; Kosjek, T.; van Nuijs, A.L.; Heath, E.; Neels, H.; Covaci, A. In vitro Phase I and Phase II metabolism of alpha-pyrrolidinovalerophenone (alpha-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol. Anal. Bioanal. Chem. 2015, 407, 5803–5816. [Google Scholar] [CrossRef] [PubMed]
- Tyrkko, E.; Pelander, A.; Ketola, R.A.; Ojanpera, I. In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry. Anal. Bioanal. Chem. 2013, 405, 6697–6709. [Google Scholar] [CrossRef] [PubMed]
- Franski, R.; Gierczyk, B.; Kasperkowiak, M.; Jankowski, W.; Hoffmann, M. The mechanism of water loss from protonated cathinones. Rapid Commun. Mass Spectrom. 2020, 34, e8617. [Google Scholar] [CrossRef]
- Sauer, C.; Peters, F.T.; Haas, C.; Meyer, M.R.; Fritschi, G.; Maurer, H.H. New designer drug alpha-pyrrolidinovalerophenone (PVP): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2009, 44, 952–964. [Google Scholar] [CrossRef]
- Ellefsen, K.N.; Wohlfarth, A.; Swortwood, M.J.; Diao, X.; Concheiro, M.; Huestis, M.A. 4-Methoxy-alpha-PVP: In silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicol. 2016, 34, 61–75. [Google Scholar] [CrossRef] [Green Version]
- Martignoni, M.; Groothuis, G.M.; de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2006, 2, 875–894. [Google Scholar] [CrossRef]
- Miles, K.K.; Stern, S.T.; Smith, P.C.; Kessler, F.K.; Ali, S.; Ritter, J.K. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: Evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab. Dispos. 2005, 33, 1513–1520. [Google Scholar] [CrossRef] [Green Version]
- Shiratani, H.; Katoh, M.; Nakajima, M.; Yokoi, T. Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab. Dispos. 2008, 36, 1745–1752. [Google Scholar] [CrossRef] [PubMed]
- Fisher, M.B.; Paine, M.F.; Strelevitz, T.J.; Wrighton, S.A. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 2001, 33, 273–297. [Google Scholar] [CrossRef]
- Maurer, H.H.; Wissenbach, D.K.; Weber, A.A. Maurer/Wissenbach/Weber MWW LC-MSn Library of Drugs, Poisons, and Their Metabolites, 2nd ed.; Wiley-VCH: Weinheim, Germany, 2018. [Google Scholar]
- Olesti, E.; De Toma, I.; Ramaekers, J.G.; Brunt, T.M.; Carbo, M.L.; Fernandez-Aviles, C.; Robledo, P.; Farre, M.; Dierssen, M.; Pozo, O.J.; et al. Metabolomics predicts the pharmacological profile of new psychoactive substances. J. Psychopharmacol. 2019, 33, 347–354. [Google Scholar] [CrossRef] [PubMed]
- Bouhifd, M.; Hartung, T.; Hogberg, H.T.; Kleensang, A.; Zhao, L. Review: Toxicometabolomics. J. Appl. Toxicol. 2013, 33, 1365–1383. [Google Scholar] [CrossRef] [PubMed]
- Milburn, M.V.; Ryals, J.A.; Guo, L. Toxicometabolomics. In A Comprehensive Guide to Toxicology in Nonclinical Drug Development; Academic Press: Cambridge, MA, USA, 2013; pp. 875–891. [Google Scholar] [CrossRef]
- Wishart, D.S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A.C.; Young, N.; Cheng, D.; Jewell, K.; Arndt, D.; Sawhney, S.; et al. HMDB: The Human Metabolome Database. Nucleic Acids Res. 2007, 35, D521–D526. [Google Scholar] [CrossRef]
- Nielsen, K.L.; Telving, R.; Andreasen, M.F.; Hasselstrom, J.B.; Johannsen, M. A Metabolomics Study of Retrospective Forensic Data from Whole Blood Samples of Humans Exposed to 3,4-Methylenedioxymethamphetamine: A New Approach for Identifying Drug Metabolites and Changes in Metabolism Related to Drug Consumption. J. Proteome Res. 2016, 15, 619–627. [Google Scholar] [CrossRef]
- Hack, S.P.; Christie, M.J. Adaptations in adenosine signaling in drug dependence: Therapeutic implications. Crit. Rev. Neurobiol. 2003, 15, 235–274. [Google Scholar] [CrossRef]
- Brown, R.M.; Short, J.L. Adenosine A(2A) receptors and their role in drug addiction. J. Pharm. Pharmacol. 2008, 60, 1409–1430. [Google Scholar] [CrossRef]
- Filip, M.; Zaniewska, M.; Frankowska, M.; Wydra, K.; Fuxe, K. The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction. Curr. Med. Chem. 2012, 19, 317–355. [Google Scholar] [CrossRef]
- Ballesteros-Yanez, I.; Castillo, C.A.; Merighi, S.; Gessi, S. The Role of Adenosine Receptors in Psychostimulant Addiction. Front. Pharmacol. 2017, 8, 985. [Google Scholar] [CrossRef]
- Borbely, A.A.; Daan, S.; Wirz-Justice, A.; Deboer, T. The two-process model of sleep regulation: A reappraisal. J. Sleep Res. 2016, 25, 131–143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Borea, P.A.; Gessi, S.; Merighi, S.; Vincenzi, F.; Varani, K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol. Rev. 2018, 98, 1591–1625. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Radulovacki, M. Role of adenosine in sleep in rats. Rev. Clin. Basic Pharm. 1985, 5, 327–339. [Google Scholar] [PubMed]
- Khamis, M.M.; Adamko, D.J.; El-Aneed, A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom. Rev. 2017, 36, 115–134. [Google Scholar] [CrossRef]
- Bartoli, F.; Misiak, B.; Callovini, T.; Cavaleri, D.; Cioni, R.M.; Crocamo, C.; Savitz, J.B.; Carra, G. The kynurenine pathway in bipolar disorder: A meta-analysis on the peripheral blood levels of tryptophan and related metabolites. Mol. Psychiatry 2021, 26, 3419–3429. [Google Scholar] [CrossRef]
- Wonodi, I.; Stine, O.C.; Sathyasaikumar, K.V.; Roberts, R.C.; Mitchell, B.D.; Hong, L.E.; Kajii, Y.; Thaker, G.K.; Schwarcz, R. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry 2011, 68, 665–674. [Google Scholar] [CrossRef] [Green Version]
- Eskelund, A.; Li, Y.; Budac, D.P.; Muller, H.K.; Gulinello, M.; Sanchez, C.; Wegener, G. Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression-like behavior. J. Neurochem. 2017, 142, 118–131. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hemmer, S.; Wagmann, L.; Pulver, B.; Westphal, F.; Meyer, M.R. In Vitro and In Vivo Toxicometabolomics of the Synthetic Cathinone PCYP Studied by Means of LC-HRMS/MS. Metabolites 2022, 12, 1209. https://doi.org/10.3390/metabo12121209
Hemmer S, Wagmann L, Pulver B, Westphal F, Meyer MR. In Vitro and In Vivo Toxicometabolomics of the Synthetic Cathinone PCYP Studied by Means of LC-HRMS/MS. Metabolites. 2022; 12(12):1209. https://doi.org/10.3390/metabo12121209
Chicago/Turabian StyleHemmer, Selina, Lea Wagmann, Benedikt Pulver, Folker Westphal, and Markus R. Meyer. 2022. "In Vitro and In Vivo Toxicometabolomics of the Synthetic Cathinone PCYP Studied by Means of LC-HRMS/MS" Metabolites 12, no. 12: 1209. https://doi.org/10.3390/metabo12121209